CHANCE - Candesartan in Hypertrophic Cardiomyopathy

Status Active, not recruiting

Clinical Trial Summary

The primary hypothesis of the study is that treatment with AT1-R antagonist in patients with nonobstructive form of HCM will be first save, second will cause regression of myocardial hypertrophy.

Clinical Trial Description

Patients will be randomly assigned in 1:1 ratio either to candesartan (target dose 32 mg once daily) or matching placebo. The initial dose of the study drug will be 8 mg once daily. Study drug dose will be then doubled as tolerated every 2 weeks while aiming for a target dose of 32 mg once daily. Monitoring of blood pressure, serum creatinine, serum potassium and pressure gradient in LV outflow tract will be performed during dose increase. Patients will be observed clinically at 3, 6, and 12 months after the maintenance dose was reached. Exercise tolerance will be assessed by bicycle ergometry, presence of malignant arrhythmias by Holter monitoring, extent of LV hypertrophy by 2-dimensional echocardiography, and LV outflow tract pressure gradient by Doppler echocardiography at baseline and 12-month follow-up. ;

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00430833
Study type	Interventional
Source	Charles University, Czech Republic
Contact
Status	Active, not recruiting
Phase	Phase 2

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03249272` - Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve	Phase 4
Recruiting	`NCT03846297` - Optimisation of Decision Making for Defibrillator Implantation in Hypertrophic Cardiomyopathy
Completed	`NCT02806479` - Hypertrophic Cardiomyopathy Pilot Study
Active, not recruiting	`NCT01225978` - Refining Information Technology Support for Genetics in Medicine	N/A
Completed	`NCT00001632` - Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart Disease	N/A
Completed	`NCT00001534` - Long Term Effects of Enalapril and Losartan on Genetic Heart Disease	N/A
Enrolling by invitation	`NCT04050579` - OPIE in the Thin Interventricular Septum	N/A
Completed	`NCT03537183` - Will Elevated Left Ventricle Filling Pressures Decrease by a Group Exercise Program in Patients With Hypertrophic CardioMyopathy?	N/A
Completed	`NCT02590809` - Hypertrophic Cardiomyopathy Symptom Release by BX1514M	Phase 2
Completed	`NCT00001396` - Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy of Children With Obstructive Hypertrophic Cardiomyop...	Phase 1
Active, not recruiting	`NCT03723655` - A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM	Phase 2/Phase 3
Completed	`NCT05135871` - Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects	Phase 1
Completed	`NCT04129905` - Assessment of the Relations Between Endothelial and Venous Dysfunctions and Left Ventricular Obstruction in Genetic Hypertrophic Cardiomyopathies	N/A
Recruiting	`NCT03061994` - Metabolomic Study of All-age Cardiomyopathy	N/A
Completed	`NCT02234336` - Assessment of Wall Thickness in Hypertrophic Cardiomyopathy
Recruiting	`NCT00221832` - Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases	N/A
Not yet recruiting	`NCT03706001` - Efficacy of Psychotherapy for Improving Quality of Life in Patients With Hypertrophic Cardiomyopathy and Depression	N/A
Recruiting	`NCT06169358` - Screening Patients With Fabry Disease in Patients With Hypertrophic Cardiomyopathy or Left Ventricular Hypertrophy
Not yet recruiting	`NCT04090437` - HCM-AF Ablation With ACUTUS	N/A
Completed	`NCT04402268` - Efficacy of Risk Assessment for Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy